Next Article in Journal
CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma
Next Article in Special Issue
First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination
Previous Article in Journal
Thirty-Five-Year History of Desialylated Lipoproteins Discovered by Vladimir Tertov
Previous Article in Special Issue
The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Lung Inflammation Predictors in Combined Immune Checkpoint-Inhibitor and Radiation Therapy—Proof-of-Concept Animal Study

Department of Radiation Oncology, Leonard M. Miller School of Medicine, University of Miami, 1475 NW 12th Ave., Suite 1500, Miami, FL 33136, USA
*
Author to whom correspondence should be addressed.
Biomedicines 2022, 10(5), 1173; https://doi.org/10.3390/biomedicines10051173
Submission received: 14 April 2022 / Revised: 28 April 2022 / Accepted: 6 May 2022 / Published: 19 May 2022
(This article belongs to the Special Issue State-of-the-Art Immunology and Immunotherapy in USA)

Abstract

Purpose: Combined radiotherapy (RT) and immune checkpoint-inhibitor (ICI) therapy can act synergistically to enhance tumor response beyond what either treatment can achieve alone. Alongside the revolutionary impact of ICIs on cancer therapy, life-threatening potential side effects, such as checkpoint-inhibitor-induced (CIP) pneumonitis, remain underreported and unpredictable. In this preclinical study, we hypothesized that routinely collected data such as imaging, blood counts, and blood cytokine levels can be utilized to build a model that predicts lung inflammation associated with combined RT/ICI therapy. Materials and Methods: This proof-of-concept investigational work was performed on Lewis lung carcinoma in a syngeneic murine model. Nineteen mice were used, four as untreated controls and the rest subjected to RT/ICI therapy. Tumors were implanted subcutaneously in both flanks and upon reaching volumes of ~200 mm3 the animals were imaged with both CT and MRI and blood was collected. Quantitative radiomics features were extracted from imaging of both lungs. The animals then received RT to the right flank tumor only with a regimen of three 8 Gy fractions (one fraction per day over 3 days) with PD-1 inhibitor administration delivered intraperitoneally after each daily RT fraction. Tumor volume evolution was followed until tumors reached the maximum size allowed by the Institutional Animal Care and Use Committee (IACUC). The animals were sacrificed, and lung tissues harvested for immunohistochemistry evaluation. Tissue biomarkers of lung inflammation (CD45) were tallied, and binary logistic regression analyses were performed to create models predictive of lung inflammation, incorporating pretreatment CT/MRI radiomics, blood counts, and blood cytokines. Results: The treated animal cohort was dichotomized by the median value of CD45 infiltration in the lungs. Four pretreatment radiomics features (3 CT features and 1 MRI feature) together with pre-treatment neutrophil-to-lymphocyte (NLR) ratio and pre-treatment granulocyte-macrophage colony-stimulating factor (GM-CSF) level correlated with dichotomized CD45 infiltration. Predictive models were created by combining radiomics with NLR and GM-CSF. Receiver operating characteristic (ROC) analyses of two-fold internal cross-validation indicated that the predictive model incorporating MR radiomics had an average area under the curve (AUC) of 0.834, while the model incorporating CT radiomics had an AUC of 0.787. Conclusions: Model building using quantitative imaging data, blood counts, and blood cytokines resulted in lung inflammation prediction models justifying the study hypothesis. The models yielded very-good-to-excellent AUCs of more than 0.78 on internal cross-validation analyses.
Keywords: lung; inflammation; pneumonitis; immunotherapy; radiotherapy; prediction; model; imaging; blood; bllod counts; cytokines; murine lung; inflammation; pneumonitis; immunotherapy; radiotherapy; prediction; model; imaging; blood; bllod counts; cytokines; murine

Share and Cite

MDPI and ACS Style

Spieler, B.; Giret, T.M.; Welford, S.; Totiger, T.M.; Mihaylov, I.B. Lung Inflammation Predictors in Combined Immune Checkpoint-Inhibitor and Radiation Therapy—Proof-of-Concept Animal Study. Biomedicines 2022, 10, 1173. https://doi.org/10.3390/biomedicines10051173

AMA Style

Spieler B, Giret TM, Welford S, Totiger TM, Mihaylov IB. Lung Inflammation Predictors in Combined Immune Checkpoint-Inhibitor and Radiation Therapy—Proof-of-Concept Animal Study. Biomedicines. 2022; 10(5):1173. https://doi.org/10.3390/biomedicines10051173

Chicago/Turabian Style

Spieler, Benjamin, Teresa M. Giret, Scott Welford, Tulasigeri M. Totiger, and Ivaylo B. Mihaylov. 2022. "Lung Inflammation Predictors in Combined Immune Checkpoint-Inhibitor and Radiation Therapy—Proof-of-Concept Animal Study" Biomedicines 10, no. 5: 1173. https://doi.org/10.3390/biomedicines10051173

APA Style

Spieler, B., Giret, T. M., Welford, S., Totiger, T. M., & Mihaylov, I. B. (2022). Lung Inflammation Predictors in Combined Immune Checkpoint-Inhibitor and Radiation Therapy—Proof-of-Concept Animal Study. Biomedicines, 10(5), 1173. https://doi.org/10.3390/biomedicines10051173

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop